• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: C.R. BARD, INC. (COVINGTON) -1018233 CONTIGEN® BARD® COLLAGEN IMPLANT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

C.R. BARD, INC. (COVINGTON) -1018233 CONTIGEN® BARD® COLLAGEN IMPLANT Back to Search Results
Catalog Number 651005
Device Problems Entrapment of Device (1212); Patient-Device Incompatibility (2682)
Patient Problems Abdominal Pain (1685); Adhesion(s) (1695); Erosion (1750); Calcium Deposits/Calcification (1758); Micturition Urgency (1871); Hypersensitivity/Allergic reaction (1907); Incontinence (1928); Unspecified Infection (1930); Inflammation (1932); Liver Damage/Dysfunction (1954); Internal Organ Perforation (1987); Overdose (1988); Pain (1994); Scar Tissue (2060); Scarring (2061); Tissue Damage (2104); Urinary Tract Infection (2120); Stenosis (2263); Therapeutic Response, Decreased (2271); Urinary Frequency (2275); Reaction (2414); Obstruction/Occlusion (2422); Prolapse (2475); Ambulation Difficulties (2544); Blood Loss (2597); Dysuria (2684); Test Result (2695); Fibrosis (3167); No Code Available (3191)
Event Type  Injury  
Manufacturer Narrative
The sample was not returned.The finished product met all specifications prior to being released for general distribution.The instructions for use which accompanies all devices currently addresses potential risks associated with surgically implanted materials.The instructions for use states in the adverse events: urological applications: adverse events associated with treatment may include but are not limited to: worsened incontinence; urinary retention; urinary tract infection; and/or localized responses (including swelling, erythema, induration, infection, necrosis, abscess formation, and/or hypersensitivity response).Slight discomfort and mild bleeding will probably occur at the injection site immediately following the injection procedure.In the clinical evaluation, approximately 2% of treated patients reported pain at the injection site or injection site injury.Transient gross hematuria may occur immediately following the injection procedure.In the clinical evaluation of contigen implant, postprocedure hematuria occurred in approximately 2% of treated patients.The patient should be told to report increasing discomfort or swelling to the physician.(b)(4) the information provided by bard represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bard.
 
Event Description
It was reported in the patient's medical records that as a result of having the product implanted, the patient has experienced pain, extrusion, unspecified urinary problems, organ perforation, recurrence, dyspareunia, vaginal scarring (scarring), erosion, infection, unspecified bowel problems, adhesions, urinary stress incontinence, internal sphincter deficiency, cystocele (prolapse), enterocele, chronic interstitial cystitis (inflammation), suprapubic/abdominal pain (abdominal pain), lumbago, urinary frequency, urinary urgency, dysuria, bladder calculus, foreign body in bladder (foreign body in patient), ulcerative colitis (ulceration), calcification, allergies, abnormal gait, overdose, partial small bladder obstruction (obstruction), inflammatory mass in colon, strictures, scar tissue, mixed portal inflammation, interlobular bile duct injury, periductal histiocytes, steatohepatitis/steatosis, perisinusoidal/portal/septal fibrosis (fibrosis), elevated liver function studies, acute and chronic serositis, lymph node reactive changes, cholelithiasis, adenomyosis of gallbladder wall, blood loss, and required additional surgical and non-surgical interventions.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CONTIGEN® BARD® COLLAGEN IMPLANT
Type of Device
CONTIGEN® BARD® COLLAGEN IMPLANT
Manufacturer (Section D)
C.R. BARD, INC. (COVINGTON) -1018233
8195 industrial blvd.
covington GA 30014
Manufacturer (Section G)
C.R. BARD, INC. (COVINGTON)
8195 industrial blvd.
covington GA 30014
Manufacturer Contact
christy lewis
8195 industrial blvd.
covington, GA 30014
7707846100
MDR Report Key5015997
MDR Text Key23525397
Report Number1018233-2015-00297
Device Sequence Number1
Product Code LNM
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P900030
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type other
Reporter Occupation Attorney
Report Date 07/27/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received08/19/2015
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date07/31/2009
Device Catalogue Number651005
Device Lot NumberCVQH0029
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Was the Report Sent to FDA? No
Device Age2 MO
Event Location Hospital
Date Manufacturer Received07/27/2015
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured08/25/2006
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age42 YR
-
-